H9 CBFA2T3-GLIS2, H9 ETO2-GLIS2
WAe009-A-40
General#
Cell Line |
|
hPSCreg Name | WAe009-A-40 |
Alternative name(s) |
H9 CBFA2T3-GLIS2, H9 ETO2-GLIS2
|
Cell line type | Human embryonic stem cell (hESC) |
Last update | 15th June 2020 |
User feedback | |
Provider |
|
Generator | Centre for Genomics and Oncological Research (GENYO) |
External Databases |
|
BioSamples | SAMEA7124963 |
CLO | CLO_0102927 |
Cellosaurus | CVCL_WM07 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Subclone of |
Donor Information#
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Family history | NO |
Is the medical history available upon request? | NO |
Is clinical information available? | NO |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA7768918 |
Ethics#
Also have a look at the ethics information for the parental line
WAe009-A
.
hESC Derivation#
Date of derivation | 1998-01-01 |
Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
PGD Embryo? |
No |
Derived under xeno-free conditions? |
Yes |
Derivation under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
No characterisation data could be found for this subclone. Please open parental cell line WAe009-AGenotyping#
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification#
Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.